Treatment of patients with hepatitis C virus on the waiting list.
1. Over 90% of patients with hepatitis C on the waiting list might be candidates for therapy with interferon plus ribavirin. 2. One must exercise caution in the treatment of these patients. Those with Child-Turcotte-Pugh score >11 or Model for End-Stage Liver Disease score >25 should be excluded from treatment. 3. Sustained virologic response (hepatitis C virus RNA-negative) is mainly dependent on viral genotype, with 50% of genotype 2 and 3 patients achieving sustained virologic response. 4. The ability to achieve sustained virologic response in genotype 1 patients is dependent on dose and duration of treatment. 5. Patients rendered hepatitis C virus RNA-negative pretransplantation may not experience posttransplantation recurrence.
University of Colorado School of Medicine, University of Colorado Health Sciences Center, Denver, CO 80262, USA. greg.everson@uchsc.edu
Gregory T
GT
Everson
D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics; D006526:Hepatitis C / Q000188:drug therapy* / Q000601:surgery; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D008099:Liver / Q000821:virology; D016031:Liver Transplantation; D012367:RNA, Viral / Q000097:blood; D012008:Recurrence; D012254:Ribavirin / Q000627:therapeutic use*; D014850:Waiting Lists
D000998:Antiviral Agents; D016898:Interferon-alpha; D012367:RNA, Viral; D012254:Ribavirin